Abstract Details
9/08/2025 | 11:30 AM - 12:30 PM | Breakout 1 | University Hall
The parent experience: Facilitators and challenges to follow-up after identification with cCMV by universal newborn screening in Minnesota
Abstract Summary
In 2023, the Minnesota Department of Health (MDH) implemented universal newborn screening (NBS) for congenital cytomegalovirus (cCMV). Between February 6, 2023 and December 31, 2024, 291 infants were confirmed to have cCMV after identification through testing of their dried blood spots. Although the goal of universal NBS is to offer these children early and effective opportunities for intervention and short and long-term follow up, little is known about the experience following identification. The purpose of this quality improvement project is to capture the experiences of parents of children identified with cCMV and to better understand facilitators and challenges of navigating the NBS system. With an external partner, MDH developed a qualitative data collection plan to gather information on parent experiences. MDH mailed a recruitment letter to 243 families who had a child diagnosed with cCMV between February 2023 and early November 2024. Interested parents completed an online form and were scheduled for a virtual focus group. Attempts were made to group parents by the age of their child, whether symptoms were present, and type of symptom. A rapid qualitative analysis was initiated at the conclusion of the focus groups. Thirty-one parents were assigned to participate in one of six focus groups (four with parents of asymptomatic children and two with parents of symptomatic children) conducted between December 2024 and January 2025. A mix of urban and rural dwelling parents participated. One interview was completed with a parent whose primary language was Spanish. Parents described facilitators and challenges experienced in the diagnostic period, during short-term follow up, and during longitudinal follow up, with some variation reported between parents of symptomatic and asymptomatic children and rural and urban parents. General findings, emerging themes, and recommendations for improving the NBS system based on parent experiences will be presented.
Learning Objectives
- Describe three factors that facilitate a positive experience for parents after their child is identified with cCMV though universal newborn screening.
- Identify three common challenges that parents experience after their child is identified with cCMV through universal newborn screening.
- List three interventions to help improve the experience of parents after their child is identified with cCMV through universal newborn screening.
Presentation
This presentation has not yet been uploaded.
Handouts
No handouts have been uploaded.
Presenters
Jenna Hullerman Umar | Co-Author
jenna.hullerman.umar@state.mn.us;
Jenna Hullerman Umar leads short term follow-up for several conditions screened using blood spot testing, including cCMV, at the Minnesota Department of Health. She serves as the main point of contacts for specialists throughout the state who serve families completing initial follow-up testing and diagnosis after an abnormal newborn screening result. Her educational background includes a Bachelor of Arts degree in Biological/Archaeological Anthropology, and a Master of Public Health in Maternal and Child Health Epidemiology. Outside of work, Jenna enjoys reading fantasy novels, nerding out with her family on home science projects, dancing, and learning about other cultures.
ASHA DISCLOSURE
Financial -
Nonfinancial -
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Jenna Soukup | Co-Author
jenna.soukup@state.mn.us;
Jenna Soukup is a licensed, certified genetic counselor with the Newborn Screening Program at the Minnesota Department of Health. She performs result notification to healthcare providers of abnormal newborn screening results. She received her Bachelors of Science in Biochemistry at South Dakota State University and a Masters of Science in Genetic Counseling at the University of Minnesota. In her spare time, Jenna enjoys reading, hiking, tennis, and quilting with her two cats.
ASHA DISCLOSURE
Financial -
Nonfinancial -
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Lexie Barber | Co-Author
lexie.barber@state.mn.us;
Lexie Barber is an epidemiologist in the Longitudinal Follow-up unit at the Minnesota Department of Health (MDH) focusing on congenital CMV and heritable conditions. Lexie joined the team in December 2022. Previously, she worked in the infectious disease divisions at MDH and the North Dakota Department of Health working mainly in vaccine preventable diseases. Lexie received her Bachelor of Science in microbiology at North Dakota State University and her Master of Public Health in environmental health from the University of Minnesota.
ASHA DISCLOSURE
Financial - No relevant financial relationship exists.
Nonfinancial - No relevant nonfinancial relationship exists.
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Katherine Kass | Co-Author
Katherine.Kass@state.mn.us;
Katherine Kass is a public health program coordinator in the Longitudinal Follow-up unit focusing on congenital CMV at the Minnesota Department of Health. Katherine received her Bachelor of Arts in Biology, Society, and Environment and her Master of Public Health in public health policy and administration from the University of Minnesota.
ASHA DISCLOSURE
Financial -
Nonfinancial -
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Melissa Raspa | Co-Author
mraspa@rti.org ;
Melissa Raspa is a Senior Scientist and Director of the GenOmics and Translational Research Center at RTI International. Much of her research focuses on children with neurodevelopmental or rare genetic disorders and their families, with an emphasis on early identification through newborn screening. Her portfolio of works includes large-scale pilot studies, natural history studies which describe the clinical phenotype of conditions and assessing the impact on families, program evaluations, and technical assistance to state public health departments. Melissa holds a BA from Franklin & Marshall College in Lancaster, PA and a MA and PhD from the University of North Carolina at Chapel Hill.
ASHA DISCLOSURE
Financial -
Nonfinancial -
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Sara M. Andrews | Co-Author
sandrews@rti.org;
Sara Andrews is a public health analyst for the GenOmics and Translational Research Center at RTI International. Her expertise is in qualitative and mixed methods research. Sara has 15 years of experience in public health research and evaluation. For the past 8 years, she has supported research on newborn screening and rare conditions, with a focus on eliciting patient and caregiver perspectives to inform needs assessments, interventions, and clinical trial readiness.
ASHA DISCLOSURE
Financial -
Nonfinancial -
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Emily Cheves | Co-Author
echeves@rti.org;
Emily Cheves is a public health analyst in the GenOmics and Translational Research Center at RTI International for about 4 years. She supports multiple projects in rare genetic disorders and newborn screening. She primarily assists in qualitative and mixed methods research with caregivers and clinicians.
ASHA DISCLOSURE
Financial -
Nonfinancial -
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Gina Liverseed | Co-Presenter, Co-Author
gina.liverseed@state.mn.us;
Gina Liverseed is the CMV Nurse Specialist in the Children and Youth with Special Health Needs section at the Minnesota Department of Health. In this role, she is responsible for coordinating the longitudinal follow-up of children identified with congenital CMV and providing education about CMV to public and provider audiences. She holds Bachelor and Master of Nursing degrees from the University Minnesota and a Doctor of Nursing Practice degree from the University of North Dakota. Gina has over 20 years of experience working as a maternal-child health nurse and a Women’s Health Nurse Practitioner. She has a special interest in perinatal infectious disease.
ASHA DISCLOSURE
Financial - No relevant financial relationship exists.
Nonfinancial - No relevant nonfinancial relationship exists.
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Bridget Walde | POC-Point of Contact, Primary Presenter, Author, Co-Author
bridget.walde@state.mn.us;
Bridget Walde is a Planner in the Longitudinal Follow-up Unit for the Minnesota Department of Health (MDH). She supports the work of the Early Hearing Detection and Intervention program and other projects related to long-term follow-up for children with newborn screening conditions. Bridget has over 5 years of experience in the implementation of culturally responsive programming with an emphasis in supporting children and adults with disabilities. Bridget graduated from Saint Louis University with her Master of Public Health and a concentration in maternal and child health.
ASHA DISCLOSURE
Financial - Receives Salary for Employment from Minnesota Department of Health.
Nonfinancial - No relevant nonfinancial relationship exists.
AAA DISCLOSURE
Financial - Receives support from Minnesota Department of Health for Minnesota Department of Health is my employer. .